Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients

Leukemia
Claire LucasR E Clark

Abstract

High cancerous inhibitor of PP2A (CIP2A) protein levels at diagnosis of chronic myeloid leukaemia (CML) are predictive of disease progression in imatinib-treated patients. It is not known whether this is true in patients treated with second generation tyrosine kinase inhibitors (2G TKI) from diagnosis, and whether 2G TKIs modulate the CIP2A pathway. Here, we show that patients with high diagnostic CIP2A levels who receive a 2G TKI do not progress, unlike those treated with imatinib (P=<0.0001). 2G TKIs induce more potent suppression of CIP2A and c-Myc than imatinib. The transcription factor E2F1 is elevated in high CIP2A patients and following 1 month of in vivo treatment 2G TKIs suppress E2F1 and reduce CIP2A; these effects are not seen with imatinib. Silencing of CIP2A, c-Myc or E2F1 in K562 cells or CML CD34+ cells reactivates PP2A leading to BCR-ABL suppression. CIP2A increases proliferation and this is only reduced by 2G TKIs. Patients with high CIP2A levels should be offered 2G TKI treatment in preference to imatinib. 2G TKIs disrupt the CIP2A/c-Myc/E2F1 positive feedback loop, leading to lower disease progression risk. The data supports the view that CIP2A inhibits PP2Ac, stabilising E2F1, creating a CIP2A/c-Myc/E2F1 pos...Continue Reading

References

Sep 18, 1992·Cell·C L SawyersO N Witte
Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·E FeinsteinE Canaani
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·H AhujaM J Cline
Apr 4, 1997·The Journal of Biological Chemistry·M C Birchenall-RobertsS J Kim
Apr 1, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Suneel D Mundle, Gurveen Saberwal
Feb 26, 2004·Blood·Bruno Calabretta, Danilo Perrotti
Nov 10, 2005·PLoS Biology·Ganna BilousovaJames DeGregori
May 11, 2006·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Milica StrnadDragana Stamatović
Apr 12, 2007·Cell Cycle·Edward V Prochownik, Youjun Li
Jul 17, 2007·Cell·Melissa R JunttilaJukka Westermarck
Jun 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugues de LavalladeDavid Marin
Jul 3, 2008·Nature·Shih-Yin TsaiGustavo Leone
Nov 26, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Archana MukhopadhyayBesim Ogretmen
May 28, 2009·Journal of the National Cancer Institute·Anchit KhannaAri Ristimäki
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christophe CômeJukka Westermarck
Sep 25, 2009·Nature Reviews. Cancer·Shirley Polager, Doron Ginsberg
May 8, 2010·Differentiation; Research in Biological Diversity·Laura KerosuoKirmo Wartiovaara
Sep 16, 2010·Annals of Surgical Oncology·Qian-Ze DongEn-Hua Wang
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinLetizia Foroni
Jan 1, 2010·Cancer Biomarkers : Section a of Disease Markers·Lisa P HuangJason P Trama
Feb 3, 2012·Cancer Research·David Engelmann, Brigitte M Pützer
Apr 28, 2012·Breast Cancer Research : BCR·Ling-Ming TsengKuen-Feng Chen
Aug 1, 2012·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Hui HeYongfeng Liu
Jan 24, 2013·Cancer Medicine·Lisa P HuangJason P Trama
Sep 4, 2013·The Journal of Clinical Investigation·Paolo NevianiDanilo Perrotti

❮ Previous
Next ❯

Citations

Apr 20, 2016·Frontiers in Oncology·Elena ArriazuMaría D Odero
Feb 9, 2017·EMBO Reports·Jiao WangJukka Westermarck
Jun 8, 2018·Current Medicinal Chemistry·Enrico ZanforlinGiovanni Ribaudo
Jan 14, 2018·Molecular Cancer Research : MCR·Shuhei EnjojiKoichi Sato
Jul 20, 2018·Science Translational Medicine·Otto KaukoJukka Westermarck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.